ChemicalBook > CAS DataBase List > AZD2098

AZD2098

CAS No.566203-88-1
Chemical Name:AZD2098
CBNumber:CB63175527
Molecular Formula:C11H9Cl2N3O3S
Formula Weight:334.18
MOL File:566203-88-1.mol

AZD2098 Property

Melting point 185-186°C
Boiling point 489.3±55.0 °C(Predicted)
Density 1.569±0.06 g/cm3(Predicted)
storage temp. 2-8°C
solubility Soluble in DMSO (>25 mg/ml)
pka 5.56±0.40(Predicted)
form powder
color white to beige
Stability Stable for 1 year as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
UNSPSC Code 51111800
NACRES NA.77

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Hazard statements
Precautionary statements

AZD2098 Price More Price(2)

Brand: Sigma-Aldrich(India)
Product number: SML2272
Product name : AZD-2098
Purity: ≥98% (HPLC)
Packaging: 5MG
Price: ₹10684.28
Updated: 2022/06/14
Buy: Buy

Brand: Sigma-Aldrich(India)
Product number: SML2272
Product name : AZD-2098
Purity: ≥98% (HPLC)
Packaging: 25MG
Price: ₹43061.85
Updated: 2022/06/14
Buy: Buy

AZD2098 Chemical Properties,Usage,Production

Description AZD-2098 (566203-88-1) is a potent, orally bioavailable antagonist of CCR4 (pIC50 = 7.8(h), 8.0(r), 8.0(m), 7.6(d)).1 Inactive at CXCR1/2, CCR1, CCR2b, CCR5, CCR7, and CCR8 @ 10 μM.
Uses AZD-2098 is a potent and selective agonist of CCR4 chemokine receptor with IC50 values ranging from 10 to 25 nM across different species. CCR4 is involved in activation and migration of Th2 lymphocytes to the lungs in response to allergens. Treating sensitised rats results in reduced inflammation of lung tissue.
Biochem/physiol Actions AZD-2098 is an orally active, potent and selective CCR4 antagonist (pIC50 = 7.8/8.0/8.0/7.6 against CCL22 binding to human/mouse/rat/dog CCR4; inactive toward CXCR1/2 & CCR1/2b/5/7/8 at 10 μM) with little or no activity toward a panel of ～120 receptors/enzymes. AZD-2098 effectively inhibits chemokine-induced cellular responses in vitro (pIC50 = 7.5 against CCL22-induced calcium influx in hCCR4-expressing CHO cells; pIC50 = 6.3 against CCL17- or CCL22-induced chemotaxis of primary human Th2 cells) and exhibits efficacy against antigen-induced inflammatory response among ovalbumin-sensitized rats in vivo (Emax = 7.5 μmol/kg p.o.; 1 h before and every 12 h after antigen challenge).

in vivo

AZD2098 (73.5-5.0 μg/kg; p.o.; BID; twice a day; 1 hour before and every 12 hours after antigen challenge) exhibits efficacy against antigen-induced inflammatory response among ovalbumin-sensitized rats, and the changes are first visible at a dose of 0.22 μmol/kg and maximal at 7.5 μmol/kg^[1].

Animal Model:	Brown-Norway rats^[1]
Dosage:	73.5 μg/kg, 250.6 μg/kg, 735.2 μg/kg, 1.0 mg/kg, 2.5 mg/kg, 5.0 mg/kg
Administration:	Oral administration; twice a day; 1 hour before and every 12 hours after antigen challenge
Result:	Exhibits efficacy against antigen-induced inflammatory response among ovalbumin-sensitized rats.

IC 50 CCR4
storage Store at +4°C
References Kindon et al. (2017), Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists; ACS Med. Chem. Lett. 8 981